31.73 USD
▼+0.08-1.31%
盘后 24.01 0.00%
2026-09-03
市值
$441.61M
市盈率
—
EPS
-0.29
股息率
—
52 周区间
12.95 – 35.50
成交量
89.61K
Beta
—
目标价
—
52W 低 12.9552W 高 35.50
价格走势
公司简介
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.